ChainGen Bio Information

ChainGen Bio (“CGB”) is a biotech company focused on discovering and developing disease-modifying therapies using its proprietary drug delivery technologies. CGB's platform includes proprietary TfR binding modules and innovative conjugation technologies designed to enable the transport of various therapeutic cargoes across the blood-brain barrier (BBB) and to muscle tissues. The current focus is on CNS and neuromuscular diseases. This versatile platform is being applied to multiple targets and modalities, resulting in the creation of BBB-crossing oligonucleotide and antibody therapies. The company is also developing advanced therapies, such as antibody-RNA conjugates with potential for neuromuscular diseases. For inquiries, please contact info@chaingenbio.com